Transcriptomics

Dataset Information

0

Decoding the immune checkpoint signatures in human atherosclerosis: implications of type 2 diabetes and lipid-lowering intervention [mouse_plaque_scRNAseq]


ABSTRACT: Immune checkpoint inhibitor (ICI) therapies in cancer accelerate atherosclerosis progression. Here, we have charted the landscape of immune checkpoint gene expression and defined the network of disease-relevant interactions with single-cell resolution. We found that signaling through PD-1 and CTLA4 is driven by a population of dendritic cells enriched for FSCN1 that can be derived from peripheral blood cells following anti-PD-1 or -CTLA4 treatment ex vivo. Type 2 diabetes dampened plaque PD-1 and CTLA4 signaling, showing that cardiometabolic comorbidities elicit unique responses to ICIs. Lipid-lowering therapy equalized the intensity and direction of immune checkpoint interactions in human blood, while atherosclerotic mice subjected to a lipid-lowering diet displayed both increased co-inhibitory signaling and a downregulation of inflammatory transcriptional programs in plaques. Our findings underscore the potential of lipid-lowering therapies in stabilizing immune checkpoint interactions and reducing plaque inflammation, offering new insights on atherosclerosis and cardiovascular risks in cancer patients undergoing ICI treatments.

ORGANISM(S): Mus musculus

PROVIDER: GSE246316 | GEO | 2024/10/07

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2020-05-12 | GSE145200 | GEO
2023-07-01 | GSE227437 | GEO
2020-07-22 | GSE141038 | GEO
2022-09-15 | GSE213145 | GEO
2024-11-15 | GSE277573 | GEO
2015-03-16 | GSE65503 | GEO
| PRJNA1032539 | ENA
| PRJNA1032560 | ENA
2024-02-02 | GSE248625 | GEO
2022-06-14 | GSE169688 | GEO